Unknown Digestion, Kidneys & Other Organs NIHR-supported project Cancer
An open-label study of patients with primary sclerosing cholangitis (PSC) treatedwith norucholic acid tablets
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Douglas Thorburn (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
An open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets (NUT002)
Pharmacokinetic (PK) study to investigate the pharmacokinetic profile of norucholic acid (NCA) in primary sclerosing cholangitis (PSC) patients treated with NCA capsules within open-label extension (OLE) NUC-5/PSC (NUC-011)
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis(NUC-5 )
Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients with an inadequate response to ursodeoxycholic acid
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know